Company profile
ARBUTUS BIOPHARMA CORP
NASDAQ:ABUSBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IMDUSIRAN SODIUM | phase2 | — | 2 | completed, terminated |
| AB-101 | phase1_2 | — | 3 | active |
| AB-836 | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01262235 | phase1_2 | completed | 2010-12-01 | 2015-07-01 | Arbutus Biopharma Corporation | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients |
| NCT04980482 | phase2 | completed | 2021-10-29 | 2025-03-13 | Arbutus Biopharma Corporation | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection |
| NCT02191878 | phase1_2 | completed | 2014-06-01 | 2016-05-01 | Arbutus Biopharma Corporation | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma |
| NCT02041715 | phase1 | terminated | 2014-01-01 | 2015-07-01 | Arbutus Biopharma Corporation | Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 |
| NCT01518881 | phase1 | terminated | 2012-01-01 | 2012-07-01 | Arbutus Biopharma Corporation | Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion |
FDA applications (0)
No records yet.